argenx SE

    Jurisdiction
    Netherlands
    LEI
    7245009C5FZE6G9ODQ71
    ISIN
    US04016X1019 (ARGX)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_flat 53 / 100
    Better than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    €730.37 2.2% undervalued
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €2.45B
    Gross margin
    92.7%
    EBIT
    €51.55M
    EBIT margin
    2.1%
    Net income
    €767.82M
    Net margin
    31.4%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €4.65B +90.0% €1.44B +87.2%
    €5.60B +20.5% €1.93B +34.3%
    €6.65B +18.8% €2.67B +38.1%

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: October 31, 2023

    Add to watchlist

    Notifications